Allarity Therapeutics Shares Are Trading Higher After the Company Announced That Stenoparib Shows a Clear Clinical Benefit, Leading to Early Conclusion of the Phase 2 Trial in Advanced Ovarian Cancer
Alarity Therapeutics宣佈Stenoparib顯示出明顯的臨床益處，導致晚期卵巢癌的2期試驗提前結束，此後，Alarity Therapeutics的股價走高